MD Anderson receives $9M from F. W. Bert and Mae Dean Wheeler Foundation

Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO

Credit: OHSU/Christine Torres HicksAfter a year as director of the Oregon Health and Science University’s Knight Cancer Institute, Tom Sellers has stepped down from his position. He is replaced by Lisa Coussens, chair of the Department of Cell, Developmental & Cancer Biology, who was appointed interim center director.

Dian Wang, William Tseng, Brian Van Tine appointed to new Sarcoma Subcommittee at NRG Oncology; Clifton Fuller named vice chair of Imaging Committee

Dian Wang, William Tseng, and Brian A. Van Tine were appointed to NRG Oncology’s newly formed Sarcoma Subcommittee. Clifton (Dave) Fuller was named vice chair for NRG’s Imaging Committee.

April 11, 2025

Vol.51 No.14

In Brief

Casirati, De Wolf, Persaud, Rehman awarded $260,000 research grants from DKMS

Gabriele Casirati, of Boston Children’s Hospital, Susan E. De Wolf, of Memorial Sloan Kettering Cancer Center, Stephen Persaud, of Washington University School of Medicine, and Abdur Rehman, of the University of Texas MD Anderson Cancer Center, were awarded DKMS’ research grant in honor of John A. Hansen.

April 11, 2025

Vol.51 No.14

Clinical Roundup

NK cells complexed with bispecific antibody yield high response rates in lymphoma

A novel cell therapy approach using cord blood-derived natural killer cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from the University of Texas MD Anderson Cancer Center.

April 11, 2025

Vol.51 No.14

In Brief

MD Anderson breaks ground on new Houston-area cancer center

The University of Texas MD Anderson Cancer Center on March 31 broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range of cancer services closer to those living in Southwest Houston and the surrounding areas.

April 04, 2025

Vol.51 No.13

In Brief

Jeffrey Lee named chief medical executive at MD Anderson

Jeffrey E. Lee was appointed chief medical executive at The University of Texas MD Anderson Cancer Center, effective April 1.

March 28, 2025

Vol.51 No.12

MD Anderson receives $9M from F. W. Bert and Mae Dean Wheeler Foundation

YOU MAY BE INTERESTED IN

Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO

Dian Wang, William Tseng, Brian Van Tine appointed to new Sarcoma Subcommittee at NRG Oncology; Clifton Fuller named vice chair of Imaging Committee

Casirati, De Wolf, Persaud, Rehman awarded $260,000 research grants from DKMS

NK cells complexed with bispecific antibody yield high response rates in lymphoma

MD Anderson breaks ground on new Houston-area cancer center

Jeffrey Lee named chief medical executive at MD Anderson

Renew today!

Subscriber content

MD Anderson receives $9M from F. W. Bert and Mae Dean Wheeler Foundation

YOU MAY BE INTERESTED IN

Tom Sellers steps down as director of OHSU Knight, replaced by Lisa CoussensShivaani Kummar recently named interim CEO

Dian Wang, William Tseng, Brian Van Tine appointed to new Sarcoma Subcommittee at NRG Oncology; Clifton Fuller named vice chair of Imaging Committee

Casirati, De Wolf, Persaud, Rehman awarded $260,000 research grants from DKMS

NK cells complexed with bispecific antibody yield high response rates in lymphoma

MD Anderson breaks ground on new Houston-area cancer center

Jeffrey Lee named chief medical executive at MD Anderson

Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO